Tocqueville Asset Management L.P. cut its holdings in AveXis Inc (NASDAQ:AVXS) by 49.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,640 shares of the company’s stock after selling 12,275 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in AveXis were worth $1,399,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of AveXis by 57.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after acquiring an additional 453 shares during the last quarter. Amalgamated Bank boosted its stake in shares of AveXis by 19.6% in the third quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after acquiring an additional 523 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of AveXis by 2.9% in the second quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after acquiring an additional 598 shares during the last quarter. Emory University boosted its stake in shares of AveXis by 3.4% in the fourth quarter. Emory University now owns 18,474 shares of the company’s stock worth $2,045,000 after acquiring an additional 607 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of AveXis by 0.5% in the fourth quarter. Jennison Associates LLC now owns 185,094 shares of the company’s stock worth $20,484,000 after acquiring an additional 883 shares during the last quarter. Institutional investors and hedge funds own 82.43% of the company’s stock.
In other news, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $109.75, for a total value of $1,646,250.00. Following the transaction, the insider now owns 1,808,386 shares of the company’s stock, valued at approximately $198,470,363.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total value of $195,301.60. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $195,301.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,560 shares of company stock worth $7,793,030. Corporate insiders own 18.60% of the company’s stock.
AveXis Inc (NASDAQ:AVXS) opened at $136.93 on Monday. AveXis Inc has a 12 month low of $65.23 and a 12 month high of $137.91.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($2.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.64) by ($0.91). equities research analysts expect that AveXis Inc will post -7.63 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/03/12/avexis-inc-avxs-stake-lowered-by-tocqueville-asset-management-l-p.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis Inc (NASDAQ:AVXS).
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.